

Závěr

V éře precizní medicíny je velmi důležité, aby si endokrinologie stále uvědomovala význam klasifikace nádorů na základě patologického nálezu a hodnoty biomarkerů, které mohou předpovídat dostatečnou terapeutickou odpověď. U mnoha onkologických onemocnění se stalo standardem péče zajistit přesnou subklasifikaci před stanovením terapeutických postu-

pů. V případě hypofýzy se často stále setkáváme s diagnózou „adenom hypofýzy“ nebo třeba „adenom hypofýzy produkující GH“. U pacientů s akromegalií je však nejdůležitější detailní patologické a imunohistochemické vyšetření, které může nasměrovat naše další léčebné kroky. Na to, jaké budou finální algoritmy pro výběr terapie, si však ještě musíme počkat.

Tento výstup vznikl v rámci programu Cooperatio, vědní oblasti METD.

PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Registrace v databázích:** N/A. **Projednání etickou komisí:** N/A.

LITERATURA

1. Endocrinology TLD&. Precision medicine: improving accuracy, reducing error. *Lancet Diabetes Endocrinol.* 1. listopad 2023;11(11):783.
2. Asa SL, Kucharczyk W, Ezzat S. Pituitary acromegaly: not one disease. *Endocr Relat Cancer.* 2017;24(3):C1-4.
3. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. *Endocr Pathol.* 2022;33(1):6-26.
4. 2021 WHO Classification of Tumors of the Central Nervous System: a summary | *Neuro-Oncology* | Oxford Academic [Internet]. [citován 23. leden 2024]. Available from <https://academic.oup.com/neuro-oncology/article/23/8/1231/6311214>
5. Starnoni D, Daniel RT, Marino L, et al. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. *Acta Neurochir (Wien).* 2016;158(11):2109-21.
6. Abu Dabrh AM, Mohammed K, Asi N, et al. Surgical Interventions and Medical Treatments in Treatment-Naïve Patients With Acromegaly: Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab.* 2014;99(11):4003-14.
7. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. *Nat Rev Endocrinol.* 2018;14(9):552-61.
8. Agrawal N, Ioachimescu AG. Prognostic factors of biochemical remission after transphenoidal surgery for acromegaly: a structured review. *Pituitary.* 2020;23(5):582-94.
9. Briceno V, Zaidi HA, Doucette JA, Onomichi KB, Alreshidi A, Mekary RA, et al. Efficacy of transphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. *Neurol Res.* 2017;39(5):387-98.
10. Brue T, Rahabi H, Barry A, et al. Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP). *Ann Endocrinol.* 2023;S0003-4266(23)00686-8.
11. Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. *Pituitary.* 2016;19:235-47.
12. Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. *Pituitary.* 2017;20(1):100-8.
13. Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. *Pituitary.* 2013;16(4):490-8.
14. Potorac I, Petrossians P, Daly AF, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. *Endocr Relat Cancer.* 2016;23(11):871-81.
15. Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure. *J Clin Endocrinol Metab.* 2010;95(11):4973-8.
16. Nista F, Corica G, Castelletti L, et al. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. *Front Endocrinol.* 2021;12:677919.
17. Fougner SL, Borota OC, Berg JP, et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. *Clin Endocrinol (Oxf).* 2008;68(3):458-65.
18. Ozkaya HM, Comunoglu N, Sayitoglu M, et al. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. *Pituitary.* 2018;21(4):335-46.
19. Gatto F, Feelders RA, Van Der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, et al. Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. *J Clin Endocrinol Metab.* 2013;98(1):E66-71.
20. Wildemberg LEA, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinoma to treatment with somatostatin analogs. *J Endocrinol Invest* [Internet]. leden 2013 [cited 10. 12. 2023];36(1). Available from <https://doi.org/10.3275/8305>
21. Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. *J Clin Endocrinol Metab.* 2019;104(3):915-24.
22. Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. *Eur J Endocrinol.* 2016;174(2):241-50.
23. Soukup J, Hornychova H, Manethova M, et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. *J Cell Mol Med.* 2021;25(5):2484-92.
24. Ilie MD, Tabarin A, Vasiljevic A, et al. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly—A Prospective Study. *J Clin Endocrinol Metab.* 2022;107(11):2982-91.
25. Puig-Domingo M, Gil J, Sampedro-Nuñez M, et al. Molecular profiling for acromegaly treatment: a validation study. *Endocr Relat Cancer.* 2020;27(6):375-89.
26. Trouillas J, Sassolas G, Guigard MP, et al. Relationships between pathological diagnosis and clinical parameters in acromegaly. *Metab – Clin Exp.* 1996;45:53-6.
27. Gil J, Marques-Pamies M, Sampedro M, et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. *Sci Rep.* 28. květen 2022;12(1):8979.
28. Wildemberg LE, da Silva Camacho AH, Miranda RL, et al. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. *J Clin Endocrinol Metab.* 1. červenec 2021;106(7):2047-56.
29. Albano L, Losa M, Barzaghi LR, Niranjan A, Siddiqui Z, Flickinger JC, et al. Gamma Knife Radiosurgery for Pituitary Tumors: A Systematic Review and Meta-Analysis. *Cancers.* leden 2021;13(19):4998.
30. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. *J Neurosurg.* 2007;106(5):833-8.
31. Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovannelli M, et al. The Role of Stereotactic Radiotherapy in Patients with Growth Hormone-Secreting Pituitary Adenoma. *J Clin Endocrinol Metab.* 2008;93(7):2546-52.